Congress Materials – American Academy of Dermatology (AAD 2026)
2026 American Academy of Dermatology | Mar 27-31 | Denver, CO
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Adolescents With Psoriasis in the United States: Current Treatment Landscape and Unmet Needs
Jennifer Soung, Linda Stein Gold, Nina Trenkler, Melina Taylor, Laurie Conklin, Jensen Lewis, Timothy Fitzgerald, Wesley Peters, Ya-Wen Yang, Guo Li, Mona Shahriari
This document will be available on March 27th 2026
APEX: Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis by Participant Baseline Characteristics
Philip J Mease, Christopher T Ritchlin, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, April W. Armstrong, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
This document will be available on March 27th 2026
Clinical Outcomes of Guselkumab in Biologic-Naïve Psoriasis Patients With Short and Long Disease Durations: A Real-World Study in Taiwan
Grace Hui-Min Wu, Shu-chen Chang, Yu-Jr Lin, Chia-Ling Chang, Bryan Wahking, Yongjing Zhang, Hong Qiu, Chee Jen Chang, Yu Huei Huang, Kuan-Yu Chen
This document will be available on March 27th 2026
Consistency of Skin Clearance With the Targeted Oral Peptide Icotrokinra: Results From a Large Pooled Cohort of Phase 3 Study Participants With Moderate-to-Severe Plaque Psoriasis
Linda Stein Gold, April W. Armstrong, Jennifer Soung, Ronald B. Vender, Andrew E. Pink, Joseph Cafone, Bassey Effiom Edem, Ofelia Reyes-Servin, Shu Li, Ya-Wen Yang, Mark G. Lebwohl
This document will be available on March 27th 2026
Durability of Icotrokinra (Targeted Oral Peptide) Effects in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study
Jennifer Soung, Mark G. Lebwohl, Adelaide Hebert, Andrew E. Pink, Yuling Shi, Megan Miller-Kassamali, Joseph Cafone, Jingzhi Jiang, Shu Li, Ya-Wen Yang, Lawrence Eichenfield
This document will be available on March 27th 2026
Durability of Response With Icotrokinra, a Targeted Oral Peptide, in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials
Linda Stein Gold, April W. Armstrong, Jennifer Soung, Ronald B. Vender, Álvaro González Cantero, Matthias Hoffmann, Ofelia Reyes-Servin, Bassey Effiom Edem, Kellen Cresswell, Ya-Wen Yang, Robert Bissonnette
This document will be available on March 27th 2026
Early and Durable Improvements in Patient-Reported Outcomes With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study
Jennifer Soung, Mark G. Lebwohl, Adelaide Hebert, Andrew E. Pink, H. Chih-ho Hong, Charles Iaconangelo, Joseph Cafone, Jingzhi Jiang, Shu Li, Ya-Wen Yang, Lawrence Eichenfield
This document will be available on March 27th 2026
Enhanced Effectiveness of Guselkumab as First-Line Biologic Therapy in Psoriasis: Real-World Results Over 84 Weeks From the G-REAL Study
S. Gerdes, M. Hoffmann, M.H. Segert, R. Ostendorf, D. Groß, F.J.H. Taut, L. Scharfenberger, S. Jacobsen, J. Behrens, N. Spindler, R. von Kiedrowski
This document will be available on March 27th 2026
Exposure - Response (ER) Relationships of Icotrokinra in Participants With Plaque Psoriasis: Phase 3 Results
B. Tammara, E. Bozenhardt, W. Zhou, C. DeKlotz, P. Newbold, A. Vermeulen, M.N. Samtani
This document will be available on March 27th 2026
Guselkumab Re-Treatment After Withdrawal: Rapid Regain of Disease Control in Super-Responders With Moderate-to-Severe Plaque Psoriasis - Final Week 220 Phase 3b GUIDE Findings
Khusru Asadullah, Andreas Pinter, Kilian Eyerich, Peter Weisenseel, Carle Paul, Friedemann Taut, Simmy Jacobsen, Jörg Schmitz, Judita Makuc, Nikolas Spindler, Knut Schäkel
This document will be available on March 27th 2026
Guselkumab Shows Better Long-Term Effectiveness and Drug Survival Compared to Secukinumab Through 84 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis – Results From the German Non-Interventional G-REAL Study
R. von Kiedrowski, S. Gerdes, M.H. Segert, R. Ostendorf, D. Groß, F.J.H. Taut, L. Scharfenberger, S. Jacobsen, J. Behrens, N. Spindler, M. Hoffmann
This document will be available on March 27th 2026
Patient-Level Persistence of On-Treatment Remission With Guselkumab: Pooled Results From VOYAGE 1 and VOYAGE 2 Participants With Moderate-to-Severe Plaque Psoriasis
Yayoi Tada, Peter Foley, April W. Armstrong, Joseph F. Merola, Jessie Chang, Steven Fakharzadeh, Emmanouil Rampakakis, Yu-Huei Huang, Luis Puig, Richard G. Langley
This document will be available on March 27th 2026
Retrospective Non-Interventional Chart Review of Guselkumab and Risankizumab in Swedish Patients With Plaque Psoriasis
Klas Agerberg, Matteo Bottai, Christina Wennerström, Luca Mazzurana, Enikö Sonkoly
This document will be available on March 27th 2026
Robust Icotrokinra Systemic and Skin Pharmacodynamic Effects Versus Deucravacitinib in Patients With Moderate-to-Severe Plaque Psoriasis: Results From Phase 3, ICONIC-ADVANCE-1 Study
APJ Van den Heuvel, H Li, E Chen, J Angsana, ME Polak, N Yum, C DeKlotz, N Sabins, L Stein Gold, AG Cantero, RB Warren
This document will be available on March 27th 2026
SPECTREM: Guselkumab Skin Clearance and Patient-Reported Outcome Results Across Skin and Joint Symptoms Through Week 48 in Low Body Surface Area, Moderate Plaque Psoriasis With at Least One Moderate High-Impact Site Involved
Linda Stein Gold, Kim A Papp, Richard G Langley, Bruce Strober, April W Armstrong, Robert Bissonnette, Alice B Gottlieb, James G Krueger, Joseph F Merola, Theodore Alkousakis, Mark G Lebwohl
This document will be available on March 27th 2026
Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra, a Targeted Oral Peptide: Pooled Analyses of 4 Phase 3 Placebo-Controlled Trials
Jennifer Soung, April W. Armstrong, Ronald B. Vender, Josep Riera-Monroig, Michael Sebastian, Ofelia Reyes-Servin, Bassey Effiom Edem, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Linda Stein Gold
This document will be available on March 27th 2026
VISIBLE Cohort A: Guselkumab Skin Clearance and Patient-Reported Outcomes Across Skin and Joint Symptoms Through Week 100 in Participants With Moderate-to-Severe Plaque Psoriasis Across All Skin Tones
Andrew Alexis, Adrian O Rodriguez, Geeta Yadav, Stephen K Tyring, Olivia Choi, Theodore Alkousakis, Daphne Chan, Tony Ma, Maxwell Sauder, Javier Alonso-Llamazares, Seemal R Desai
This document will be available on March 27th 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.